Stock Liao information

— Basic knowledge of stocks|Introduction to basics of stocks|Stock learning|Basic knowledge of stocks
Mobile access:m.liaochihuo.com

Chinese medicine stocks (leading stocks in the Chinese medicine sector)

Release Time:2021-04-28 Topic:National Chinese Medicine Leading Stocks Ranking Reading:62 Navigation:Stock Liao information > Health regimen > traditional Chinese medicine > Chinese medicine stocks (leading stocks in the Chinese medicine sector) phone-reading

" Featured Summary: Companies, customers include Yunnan China Tobacco, Shanghai Tobacco, Hunan China Tobacco, Mondelez, Chinese Medicine Stock Bright, Huiyuan, Totole, Jinluo and other famous companies in the industry. The company’s production bases are located in Shanghai, Guangdong, Jiangsu, Yunnan, Jiangxi, Fujian, Hong Kong, and Tswana, the leading stock of the Bo Chinese medicine sector. It can source the highest quality raw materials worldwide to provide customers with international standards and satisfaction. High-quality Chinese medicine stock products for customer specific needs."

1. Chinese medicine stocks

1. Huasheng shares 002670, issue price: 7 Chinese medicine stocks. 30 yuan, circulation: 50 million shares, subscription limit: 40,000 shares, belonging to the electrical wiring industry, we expect the company from 2011 to 2013 The annual earnings per share are respectively: RMB 0.33, RMB 0.40, and RMB 0.48.

2. The company provides a unified software platform based on innovative Chinese medicine stocks and a high-performance hardware platform, with network security as the core, integrating network security and application delivery in the field of corporate communications , The overall solution of each functional module of the basic network.

3. Currently, the controlling shareholder HKUST holds 18% of the shares of the 100% holding company of USTC, and Academician Pan holds 11.01% of the shares. All the 9 core technical personnel of Chinese medicine stocks recognized by the company Holdings.

4. Since its establishment, the company has been committed to the research and development, production and sales of Sichuan-flavored compound seasonings. The four series of "Good People", "Crane Wheel" and "Yang Yang Yang" sell well all over the country and are exported to overseas products.

5. According to the Shanghai Stock Exchange, Xiamen Tebao Bioengineering Co., Ltd. and Fujian Fuguang Investment Reminder for the current period: The total estimated amount of funds raised in this batch of Chinese medicine stocks for the exchange of Chinese medicine is 1.652 billion yuan , The total amount of IPO financing in the first quarter fell by more than 30% from the previous quarter.

6. Therefore, we estimate that the total amount of participation funds for the two new shares of Tianqi Mould and Zhongshun Jierou is about 400 billion yuan. Full participation requires 1.916 million yuan, a small capital It is recommended that TCM stocks be given priority to subscribe to Tianqi Mould, and large funds are recommended to be fully subscribed.

7. The main products include electrical polyester film, electrical polypropylene film, electrical mica tape, electrical flexible composite insulating materials, electrical layer molded products, insulating oil Chinese medicine stock paint And resin, halogen-free flame retardant sheet, electrical non-woven fabric and electrical plastics, etc.

8. The Huanxing company is a high-tech enterprise, with a national-level enterprise technology center, a post-doctoral Chinese medicine stock scientific research station, and has been approved by the Ministry of Science and Technology to establish the only national insulation in China Materials Engineering Technology Research Center.

The company was rated as "Hebei Province Famous Brand" and "The Food Industry of the Chinese Traditional Medicine Stock Country has the most growth by Hebei Provincial Administration for Industry and Commerce, China Food Industry Growth Star Selection Committee, Sugar, Tobacco and Alcohol Weekly Magazine "Sexual Enterprise", "China's Food Industry Plant Protein Beverage Benchmark Brand".

After years of development, the company, together with its "Yangyuan" and "Yangyuan Six Walnut" walnut beverages, has become one of the most recognized walnut beverage manufacturers and brands in the company’s sales area. The trademark "Chinese medicine stocks and pictures" has been recognized by the State Administration for Industry and Commerce as "China's Well-known Trademark".

Strong independent R&D and technical strength of Chinese medicine stocks, positioning the segment of emerging industry markets.

The group's mine operation, management level, mining and dressing technology, environmental governance, etc. enjoy a high reputation in the same industry. It is a member of the Zhejiang Fluorite Association. The vice-chairman unit of the Stone Professional Committee and the vice-chairman unit of the Zhejiang Mining Association.

Company 2016-In 2018, revenues were 0.85, 111, and 148 million yuan, with a compound growth rate of 48.11% from 2015 to 2018; net profits attributable to the parent were 540, 2,591, and 31.28 million yuan; net profits after deduction of Chinese medicine stocks were 503, 1130 1. The compound growth rate of revenue in the past three years has reached 27.58%.

The total amount of online fundraising of the two new shares is 1.964 billion yuan. Dongcai Technology is calculated based on the upper limit of the issue price range. Most Chinese medicine stocks can use 1.924 million yuan of subscription funds.

The issue price of Huanhang Aofei Animation is too high, but considering its unique industry attributes and its dominant position in the industry, it is expected that a higher premium will still be obtained on the first day of listing, assuming the company’s first-day pricing The price-earnings ratio reached 60 times, corresponding to the stock price of 39 yuan, an increase of 70%; Luolai Home Textiles' first-day pricing is expected to reach 40 times the price-earnings ratio, corresponding to the stock price of 38.4 yuan, an increase of 37%; Xinlitai's first-day pricing is expected to reach 46 times the price-earnings ratio, For Hairong Cold Chain: On November 19, the purchase guide will be changed. Qingdao Hairong Commercial Cold Chain Co., Ltd. will be listed on the Shanghai Stock Exchange on Monday, November 19. The Chinese medicine stock is referred to as “Hairong Cold Chain” and the stock code is 603187. The subscription code is 732187, the issue price is 32.25 yuan, and the single account subscription limit is 20,000 shares. The top grid subscription requires a market value of 200,000 yuan. The winning lottery number announcement date is November 21st, and the winning lottery payment date is Wednesday, November 21st.

Frozen funds of 860 billion yuan, higher than our expected upper limit of 700 billion yuan and the market's consensus estimate of 450 billion yuan for the TCM stock period.

Broadcom Integrated 2016-2018 net Chinese medicine stock profit compound growth rate was 9.71%. As a leader in domestic chip design, the company has domestic leading chip design and R&D advantages, brand advantages, and Broadcom integrated model The score ranks in the top 40% of new stocks within one year of listing, and we recommend paying attention.

Change line Zhilaike Chinese Medicine Stock Technology: The first new stock with a market value of 50 million yuan in Shenzhen Stock Exchange.

In general, the willingness to reduce holdings of high-valued stocks is stronger than that of low-valued Chinese medicine stocks, and the willingness to reduce holdings of stocks with high cumulative gains is stronger than that of low-rise stocks, and valuation indicators take priority over cumulative stocks. Increase.

The expected issuance price of Zhongchuang Logistics is 15.32 yuan, and the corresponding issuance PE is 22.24 times, which exceeds the monthly static price-earnings ratio of nearly one Chinese medicine stock in the G58 industry. It is expected that the issuance will be postponed with a high probability. It is recommended to declare as soon as possible! The market value threshold of 10 million yuan for the new bank A has accounted for more than 80%.

Since 2010, in the face of the rapid development of the express delivery industry, the company has quickly grasped the development opportunities of the smart express box industry and combined the company’s more than ten years of technology accumulation Advantages, independent research and development of smart express box and final Chinese medicine stock end/server software system.

Epoxy resin adhesive is the company’s main structural adhesive product, with a sales volume of 3755 tons in 2011; acrylic acid Chinese medicine stock ester adhesive is one of the company’s superior products, and the company’s modified acrylic structural adhesive has been producing and selling First among domestic enterprises; polyurethane adhesives are mainly solvent-free polyurethane laminating adhesives, which are used in the flexible packaging industry.

The average TCM stocks in the 2.8-month change of new stocks have a maximum return of 233%.

Brief introduction of the company. The company is a high-tech enterprise specializing in communication network technology services. It provides communication operators with core network, wireless network, transmission network and other network-level communication TCM stock network engineering Comprehensive technical services such as construction, maintenance and optimization, and provide comprehensive technical services such as base station supporting and tower construction and maintenance for China Tower, as well as information technology services such as customized development and integration of information system software for customers.

TCL Ace is the second largest shareholder of the Chinese Medicine Stock Company, with a shareholding ratio of 11.29%.

Second. Leading stocks in the Chinese medicine sector

Judging from the presentation of the main content of this reform by the China Securities Regulatory Commission, we believe that this reform will focus on both the primary and secondary markets: the primary market In response to the issue of high-priced new stocks; the second Chinese medicine sector's leading stock market suppresses new stock speculation.

On the whole, in the context of the acceleration of the leading stock O in the IP Chinese medicine sector, focusing on high-quality stocks with fundamentals is still the preferred strategy.

Changing lines Our target customers in this report are also mainly aimed at customers who are ready to sell after winning the new signing of leading stocks in the Chinese medicine sector, rather than customers who are planning to buy in the secondary market.

Before the issuance, the company’s actual controllers, Wenyuan and Zhang Qian, a leading stock in the Chinese medicine sector, directly or indirectly held 93.15% of the shares, and the employee shareholding platform Suzhou Yuanfen and Suzhou Yuanke jointly held 18% of the shares. Among them, employees other than the actual controllerCalculated indirect shareholding of 6.85%.

As the over-the-counter market focuses on small risk warnings, although investors have already carried out risk warnings when opening accounts for leading stocks in the Chinese medicine sector, we still remind investors of this again. IPO investment risk.

The company is mainly engaged in the research and development, production and sales of nano-scale carbon materials. The main products are carbon nanotube powder, conductive Chinese medicine sector leading stock slurry and Conductive masterbatch is used in lithium batteries, conductive plastics and other fields.

Since 2010, in the face of the rapid development of the express delivery industry, the company quickly grasped the development opportunities of the leading stock box industry in the smart fast Chinese medicine sector, combined with the company’s more than ten years of technical accumulation advantages, and independently developed smart Express mail box and terminal/server software system.

The leading stocks in the Chinese medicine sector in line-of-line revenue fluctuate with the downstream update cycle, and the overall profitability is stable.

New line today's guide, New line 1. On January 27, 2016, the third leading stock in the Chinese medicine sector will issue 1 new stock: Oriental Fashion 732377.

The 9 leading Chinese medicine stocks on the small and medium board listed on the Shenzhen Stock Exchange in July are shown in Table 2. The average increase on the first day of listing is 79%.

The company's 2016-leading stocks in the Chinese medicine sector have revenues of 0.85, 111, and 148 million in 2018, respectively, and a compound growth rate of 48.11% from 2015 to 2018; net profits attributable to the parent are 540, 2591, 3128, respectively Ten thousand yuan; net profit after deduction of 503, 1130, 1 the compound growth rate of income in the past three years reached 27.58%.

Recommendations: buy below 30 yuan, increase holdings of leading Chinese medicine stocks at 31-32 yuan, wait and see at 32-33 yuan, reduce holdings at 33-34 yuan, and sell above 34 yuan. Main conclusion: change line In February 2011, a total of 26 new shares were issued in the A-share market, with a financing scale of 25.9 billion yuan.

Before the issuance, the actual controllers of the company, Chen Wenyuan and Zhang Qian, directly or indirectly held 93.15% of the shares, and the employee shareholding platform Suzhou Yuanfen and Suzhou Yuanke jointly held 18% of the leading shares of the Chinese medicine sector. Employees other than the actual controller hold a total indirect shareholding of 6.85%.

After the new line is accepted, there will be a number of key review links, and more companies in the leading stocks of the Chinese medicine sector will be accepted in the future.

If the inquiry is difficult to reflect the price discovery power of the leading stock in the Chinese medicine sector, the degree of marketization of pricing is not high, the cumulative problem of lifting the ban on restricted stocks, the problem of institutional dual-channel subscription, the substantial fluctuation of subscription funds The impact on the currency market, how the interests of various customers are balanced, and so on.

Change line 2 The total amount of new stocks raised on the leading stocks of the Sci-tech Chinese Medicine sector: 3 billion yuan for large-cap stocks and 600 million yuan for small-cap stocks; A shares The total amount of individual new stocks raised in other sectors: large-cap stocks 2 billion yuan, small-cap stocks 600 million yuan; change line 3 expected large-cap stocks and small-cap stocks to sell gains: A-shares average 100%-175% and 150%-225, respectively %, the science and technology innovation board averages 20%-50% and 30%-60% respectively; summary of the offline placement of 4A shares in other sectors: high standards, steady start, strong supervision, and risk control "Customs," the opening of the transaction authority, corporate selection, issuance pricing, material declaration, early listing transaction supervision, system safety operation, integrity, and potential risks. Accept the time test; inquiries and pricing for bank changes will further accelerate the marketization process in the future; the break rate of new stocks in the future will be in line with international standards and become the norm; the new trading mechanism of bank changes and the increase in offline concentration will inhibit the initial stage of IPOs; There are many uncertainties in the new technology, new business format, and new profit model of the bank; the market value of the fund-raising project with a good vision of the bank needs to be confirmed in the future; the risk of delisting caused by various black swans of the bank; the bank...the company is Chinese seasoning The governing unit of the Food Association and the national key leading enterprise of agricultural industrialization.

Investment points: Huanhang is a leading IC design manufacturer in the Fabless Chinese medicine sector, focusing on SoC chip design and solutions for multimedia intelligent terminals.

There are 40 R&D personnel in the company, accounting for 20%. Chairman Zheng Tao once served as a research scientist in the leading Chinese medicine sector of Beltone in the United States. In 2010, he began to manage the company’s investment points: production and sales. A high-tech enterprise of the new type of medical equipment "capsule gastroscope".

In terms of the secondary market for new lines: We believe that the leading stocks in the Chinese medicine sector are fundamental to curbing IPO speculation by increasing supply, while strict supervision of IPO speculation is a short-term measure.

As an open R&D service platform, the company facesGlobal small molecule chemical pharmaceutical companies provide R&D services, with 26 global R&D bases/branch leaders in the Chinese medicine sector, including domestic Shanghai, Suzhou, Tianjin, Wuhan, Changzhou, Philadelphia, Sao Paulo, Atlanta, San Diego, Munich, Germany, etc. The stock structure has the ability to provide different services in all links of the new drug research and development industry chain to small molecule chemical pharmaceutical companies of different scales, types and stages of development, and continue to absorb new technologies and new talents from around the world, and keep up with the development trend of the industry. Improve their own service capabilities.

Change line 3. The proportion of offline allocation of leading stocks in the Chinese medicine sector participating in the transfer of old stocks further declined.

The average freezing of funds for each new share on the leading stocks of the Chinese medicine sector on the Internet is 48.661 million, and the average freezing of each new share for offline allotment is 1.197 million.

Leading stocks in the Chinese medicine sector have changed from core equipment to industry applications, and the entire industry chain has deployed quantum communication technology.

Skyline shares, the leading stock in the Chinese medicine sector in a new bank: subscription code 002759, subscription limit of 9500 shares, subscription price 12.02 yuan, the company's main small household appliances, electronic products, medical equipment, etc.

The company's current product application category Chinese medicine sector leading stocks mainly include 5.8G products, WIFI products, Bluetooth digital transmission, general wireless, walkie-talkie, radio transceiver, Bluetooth audio, wireless microphones, etc.

(Chinese medicine stocks) Baidu recommendation: http://www.southmoney.com/gupiao/glg/202001/4898232.html

Leading stocks in the Chinese medicine sector: https://www.baidu.com/s?wd=%E4%B8%AD%E5%8C%BB%E8%8D%AF%E6%9D%BF% E5%9D%97%E9%BE%99%E5%A4%B4%E8%82%A1&rsf=1000012&rsp=0&f=1&oq=%E4%B8%AD%E5%8C%BB%E8%8D%AF%20 %E8%82%A1%E7%A5%A8&ie=utf-8&rsv _ pq=e036d6fb0001865f&rsv _ t=bfca%2BdB%2BFxCXX0sCrlYWfo9UE&rqlang=cn&rs _ src=0&rsv rsv_pq=tfd6fb% 0001dB&rsv rsv_pq=e=tfd6fb% 00018650dB

Article Url:https://www.liaochihuo.com/info/538833.html

Label group:[stock] [stock issuance] [new shares] [Leading stock] [traditional Chinese medicine

Hot topic

Health regimen recommend

Health regimen Popular